Li Kang Biomedical Co., Ltd. Stock

Equities

6242

TW0006242001

Food Processing

End-of-day quote Taipei Exchange 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
51.8 TWD -0.19% Intraday chart for Li Kang Biomedical Co., Ltd. -0.96% -11.15%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 684M 21.11M Sales 2023 629M 19.42M Capitalization 1.56B 48.22M
Net income 2022 112M 3.46M Net income 2023 111M 3.42M EV / Sales 2022 1.54 x
Net cash position 2022 263M 8.13M Net cash position 2023 210M 6.48M EV / Sales 2023 2.15 x
P/E ratio 2022
11.8 x
P/E ratio 2023
14.2 x
Employees -
Yield 2022
3.55%
Yield 2023
-
Free-Float 33.81%
More Fundamentals * Assessed data
Dynamic Chart
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
1 day-0.19%
1 week-0.96%
Current month-0.96%
1 month-2.81%
3 months-5.30%
6 months-7.00%
Current year-11.15%
More quotes
1 week
51.50
Extreme 51.5
52.30
1 month
50.20
Extreme 50.2
53.50
Current year
50.20
Extreme 50.2
58.80
1 year
50.20
Extreme 50.2
70.52
3 years
31.06
Extreme 31.0559
71.30
5 years
24.27
Extreme 24.265
71.30
10 years
15.67
Extreme 15.6678
71.30
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 14-10-19
Members of the board TitleAgeSince
Chief Executive Officer - -
Director/Board Member - 14-08-24
Director/Board Member - 14-08-24
More insiders
Date Price Change Volume
24-05-08 51.8 -0.19% 8,857
24-05-07 51.9 +0.19% 16,465
24-05-06 51.8 -0.19% 3,850
24-05-03 51.9 -0.76% 19,762
24-05-02 52.3 0.00% 17,000

End-of-day quote Taipei Exchange, May 07, 2024

More quotes
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW